A Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Provides Outstanding Protection in Mice against Genital and Non-Genital HSV-1 Infection, Comparable to the Same Antigens Derived from HSV-1
Viruses · 2023
DOI: 10.3390/v15071483 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Kevin P Egan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Herpesvirus 1, Human, Herpes Genitalis. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
HSV-1 disease is a significant public health burden causing orofacial, genital, cornea, and brain infection. We previously reported that a trivalent HSV-2 gC2, gD2, gE2 nucleoside-modified mRNA-lipid nanoparticle (LNP) vaccine provides excellent protection against vaginal HSV-1 infection in mice. Here, we evaluated whether this HSV-2 gC2, gD2, gE2 vaccine is as effective as a similar HSV-1 mRNA LNP vaccine containing gC1, gD1, and gE1 in the murine lip and genital infection models. Mice were immunized twice with a total mRNA dose of 1 or 10 µg. The two vaccines produced comparable HSV-1 neutralizing antibody titers, and surprisingly, the HSV-2 vaccine stimulated more potent CD8+ T-cell responses to gE1 peptides than the HSV-1 vaccine. Both vaccines provided complete protection from clinical disease in the lip model, while in the genital model, both vaccines prevented death and genital disease, but the HSV-1 vaccine reduced day two vaginal titers slightly better at the 1 µg dose. Both vaccines prevented HSV-1 DNA from reaching the trigeminal or dorsal root ganglia to a similar extent. We conclude that the trivalent HSV-2 mRNA vaccine provides outstanding protection against HSV-1 challenge at two sites and may serve as a universal prophylactic vaccine for HSV-1 and HSV-2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Disease Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Acuitas Therapeutics Inc., Vancouver, BC V6T 1Z3, Canada.
- Department of Basic and Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
ORCID-Profile: Kevin P Egan, Sita Awasthi, Lauren M Hook, Mohamad-Gabriel Alameh, Harvey M Friedman
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Cancer Institute
- BioNTech
Zitieren
APA
Egan, K. P., Awasthi, S., Tebaldi, G., Hook, L. M., Naughton, A. M., Fowler, B. T., Beattie, M., Alameh, M. G., Weissman, D., Cohen, G. H., & Friedman, H. M. (2023). A Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Provides Outstanding Protection in Mice against Genital and Non-Genital HSV-1 Infection, Comparable to the Same Antigens Derived from HSV-1. Viruses. https://doi.org/10.3390/v15071483
Vancouver
Egan KP, Awasthi S, Tebaldi G, Hook LM, Naughton AM, Fowler BT, et al. A Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Provides Outstanding Protection in Mice against Genital and Non-Genital HSV-1 Infection, Comparable to the Same Antigens Derived from HSV-1. Viruses. 2023. doi:10.3390/v15071483
BibTeX
@article{Egan2023,
author = {Egan, Kevin P and Awasthi, Sita and Tebaldi, Giulia and Hook, Lauren M and Naughton, Alexis M and Fowler, Bernard T and Beattie, Mitchell and Alameh, Mohamad-Gabriel and Weissman, Drew and Cohen, Gary H and Friedman, Harvey M},
title = {A Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Provides Outstanding Protection in Mice against Genital and Non-Genital HSV-1 Infection, Comparable to the Same Antigens Derived from HSV-1},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15071483}
}
EUVIMED